Menu ≡ ╳
Many drug candidates and ongoing research studies into their efficacy received serious setbacks when COVID-19 resulted in the total closure of many trial study sites. There’s no saying when these studies will resume and bring deserving drug candidates to the market, to benefit a number of patients who need them, even today. This disruption to patient visits to trial sites for submitting data or receive drug administration has no end in sight, unless we strike off on a new path and transform our processes.
With global lockdowns, social distancing and closed borders, there’s no doubt that digitization has been a great help to many of us. Pharma companies need to focus on improving outcomes and managing costs when testing the efficacy of their drugs, not just in a randomized clinical trial, but in the market as payors and governments alike are looking for drugs with a demonstrated value before they would consider paying a premium for them. This makes it necessary to pick the right digital tools by evaluating the promised outcomes and their desirability in the scheme of things.
Virtual clinical trials have less site dependence. They depend more on telehealth and telemedicine applications. They are aligned with mobile healthcare providers and do not require the trial subjects to visit any site. The conduct all tests virtually, or at some local laboratories or mobile facilities. All consultations can happen over text messages, or audio/video calls. Trial subjects can also get the drugs and delivery devices needed shipped to their addresses, with virtual supervision and nurse assistance being offered 24×7 as support. Data gets collected virtually or through mobile healthcare providers.
Many drug sponsors are becoming suddenly more interested in participating in the digital revolution happening in pharmaceuticals and healthcare are looking for the winning strategy. How assured is digital success? How are we to choose the right initiative? The answer to such questions is not far to seek.
In these highly turbulent times, digitization steps in with various solutions to ease our passage, by:
Technology today is also helping to automate some complex decisions, and helping to streamline and improve the business processes to offer superior quality, execution times and efficiency. This is heralding a sea change in clinical trial process, as more and more sponsors are adopting tools which improve the management of their clinical trials, across geographies.
Remember, that the opportunities to adopt digital technologies are many and varied. It’s possible to really adopt digitization only when companies identify the right initiatives, and truly embrace the opportunity, whether using mobile communications, cloud-based tools and apps, advanced analytics or the Internet of Things. Here’s to more efficiency and speed-to-market and ultimate success in all your endeavors.
MaxisIT’s Clinical Trials Oversight System (CTOS) enables “data-driven digital transformation” by its complete AI enabled analytics platform from data ingestion, processing, analysis to in-time clinical intelligence by establishing value of data, improve efficiency and empower clinical stakeholders to mitigate risks or seize the opportunity. The CTOS platform helps clinical operations, clinical data management, biostatistics, and clinical R&D portfolio management by bringing clinical operations and patient data together in a single, central data hub (i.e. single-source of truth). The platform allows self-service analytics and role-based clinical intelligence enabling insights, time & cost efficiency, risk mitigation and the effective management of portfolio, data quality, patient safety, CRO/site performance management. In short, it helps you maintain an ongoing health-check on your portfolio of clinical trials, using real-time data, analytics and visualization to drive rigorous analysis of the entire dataset, allowing for proactive trial risk management.
We simplify the monitoring process, feeding all data through a single repository, running robust analytics and ultimately producing visualizations that are fit for human consumption. Because, yes, complex data analysis can produce simple insights. Real-time data ingestion, analytics and visualization empower researchers to identify errors as they occur.